Health regulator says serious side-effects possibly caused by insulin in counterfeit versions of Novo Nordisk’s Ozempic
Several people have been admitted to hospital in Austria after using suspected fake versions of Novo Nordisk’s diabetes drug Ozempic, the country’s health safety body has said, the first report of harm to users as a European hunt for counterfeiters widened.
The patients were reported to have suffered hypoglycaemia and seizures, serious side-effects that indicate that the product contained insulin instead of Ozempic’s active ingredient semaglutide, the health safety regulator Bundesamt für Sicherheit im Gesundheitswesen (BASG) said on Monday.
More Stories
Will Trump’s tariff chaos be China’s gain in global trade wars?
Revealed: Big tech’s new datacentres will take water from the world’s driest areas
Meta faces antitrust claims at trial over Instagram and WhatsApp ownership